Is XBI a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The case for XBI is simple: low-cost, diversified exposure to S&P Biotechnology Select Industry Index at a 0.35% expense ratio, anchored by names like MRNA, APGE, KYMR. If that is the exposure you want and you do not already own most of it through another fund, XBI is a strong core holding. The catch is concentration in its top names and overlap with broad-market funds you may already hold. Whether it is a buy comes down to whether you want S&P Biotechnology Select Industry Index and at what cost. Not a recommendation; Walnut is not an investment adviser.
What are you buying with XBI?
XBI tracks the S&P Biotechnology Select Industry Index, a modified equal-weighted basket of US biotech companies. It charges 0.35%. The key nuance versus the cap-weighted IBB is that XBI equal-weights its holdings, giving small and mid-cap drug developers far more sway and making it more volatile and less concentrated in a few large names.
Largest holdings (approximate as of mid-2026; verify on State Street Global Advisors (SPDR)'s fund page):
| Rank | Ticker | Company | % of XBI | |
|---|---|---|---|---|
| 1 | MRNA | Moderna, Inc. | ~1.5% | |
| 2 | APGE | Apogee Therapeutics, Inc. | ~1.4% | |
| 3 | KYMR | Kymera Therapeutics, Inc. | ~1.4% | |
| 4 | VKTX | Viking Therapeutics, Inc. | ~1.3% | |
| 5 | ERAS | Erasca, Inc. | ~1.3% | |
| 6 | PRAX | Praxis Precision Medicines, Inc. | ~1.2% | |
| 7 | TWST | Twist Bioscience Corporation | ~1.2% | |
| 8 | ORKA | Oruka Therapeutics, Inc. | ~1.2% | |
| 9 | MIRM | Mirum Pharmaceuticals, Inc. | ~1.2% | |
| 10 | RYTM | Rhythm Pharmaceuticals, Inc. | ~1.2% |
What's the case for XBI?
XBI is the SPDR S&P Biotech ETF, a modified equal-weighted fund holding roughly 150 to 160 US biotechnology companies. It tracks the S&P Biotechnology Select Industry Index and charges a 0.35% expense ratio. Because it equal-weights rather than cap-weights, XBI gives small and mid-cap biotech far more influence than a cap-weighted fund like IBB, which makes it a higher-beta, more volatile way to own the sector and a favorite proxy for the broad biotech cycle.
In its favour: it gives you S&P Biotechnology Select Industry Index exposure in one ticker at a 0.35% expense ratio, which is simple to hold and cheap to own.
What should you weigh before buying XBI?
- Cost vs alternatives: 0.35% is the fee; compare it to funds tracking a similar index.
- Concentration: check how much of XBI sits in its largest holdings (MRNA, APGE, KYMR).
- Overlap: if you already own a broad-market fund, you may already hold much of this.
- Tracking scope: XBI only gives you S&P Biotechnology Select Industry Index; it will not capture what sits outside that index.
How do you decide if XBI is a buy?
The useful question is rarely “will XBI go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how XBI would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.
The bottom line on XBI
The bottom line: XBI is a low-cost core building block for S&P Biotechnology Select Industry Index exposure, not a tactical bet on a single name. If you want S&P Biotechnology Select Industry Index exposure and the 0.35% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.
Build a portfolio around XBI with Walnut
Use XBI as your core holding, then let Walnut's AI propose thematic satellites: AI infrastructure, dividend growth, clean energy, whatever you believe in. Connect your broker, build the basket in conversation, track it as one unit.
FAQ
Is XBI a good ETF to buy?
+
Walnut is informational, not investment advice. Whether XBI fits depends on your goals, time horizon, and what you already hold. It tracks S&P Biotechnology Select Industry Index at a 0.35% expense ratio, so the questions that matter are whether you want that exposure, whether you already own it through another fund, and whether the cost is competitive for what it does.
What does XBI actually hold?
+
XBI tracks S&P Biotechnology Select Industry Index. Its largest positions include MRNA, APGE, KYMR, VKTX, ERAS and others (approximate, verify on State Street Global Advisors (SPDR)'s fund page). The holdings are what you are really buying, not the ticker.
What is XBI's expense ratio?
+
0.35% as of mid-2026. Over decades, the expense ratio is one of the few things you can control, so it is worth comparing against close alternatives that track a similar index.
Does XBI pay a dividend?
+
XBI distributes a dividend with an approximate yield of ~0.2% (mid-2026). See the XBI dividend page for how distributions work. Verify the current figure with State Street Global Advisors (SPDR).
What are the risks of buying XBI?
+
Like any index ETF, weigh concentration (how much sits in the top holdings), overlap with funds you already own, and whether S&P Biotechnology Select Industry Index matches the exposure you actually want. XBI only gives you S&P Biotechnology Select Industry Index, not what sits outside it.
How do I decide if XBI is right for me?
+
Start from your goal, then check four things: what XBI holds, its cost versus alternatives, how much it overlaps with what you already own, and whether the exposure fits your time horizon and risk tolerance. Walnut can analyze the overlap against your real holdings; you keep your broker and approve any trade.
Walnut is informational, not investment advice. Figures are approximations stamped to mid-2026; verify current data with State Street Global Advisors (SPDR) or your broker. Nothing here is a recommendation to buy, sell, or hold any security.